Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025BMJ Mental HealthOpen Access

Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuan ZhangYGYiyuan GaoYZYazhu Zou

Discussion

Loading...

Member takes

Overview

Meta-analysis shows pharmacogenomic therapy improves response rates in major depressive disorder, indicating ethnicity and severity influence effectiveness.

Key Points

  • Pharmacogenomic-guided treatment significantly improved response rates at 8 weeks, with a risk ratio of 1.23.
  • Response rates at 12 weeks were also significantly better at 1.29, indicating persistent efficacy over time.
  • The systematic review included 13 randomized controlled trials from 2013 to 2024, assessing various demographics and genetic factors.
  • Cumulative analyses suggest benefits plateau with larger genetic panels, stressing the need for cost-effective treatment strategies.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68af7df87567bf4f94ff515chttps://doi.org/10.1136/bmjment-2025-301726
View Full Paper
Ask AI
Bookmark
Share